The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Dyslipidemia and hyperglycemia are common among patients presenting with acute coronary syndromes (ACS), and patients with ACS and metabolic disorders are at increased risk for worse outcomes. Although guidelines for the diagnosis and management of dyslipidemia, diabetes, and the metabolic syndrome have been published, these guidelines have not specifically focused on the ACS patient population. Recent observational registries and clinical trials have advanced the appreciation of these disorders in ACS populations and data from these studies support aggressive efforts to diagnose and treat dyslipidemia and hyperglycemia in patients admitted for ACS.
- Cannon CP, Weintraub WS, Demopoulos LA, et al., for the TACTICS -Thrombolysis n Myocardial Infarction 18 Investigators: Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879–1887. CrossRef
- Cohen M, Demers C, Gurfinkel EP, et al., for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997, 337:447–452. CrossRef
- FRagmin and Fast Revascularization during InStability in Coronary artery disease (FRISC II) Investigators: Invasive compared with non-invasive treatment in unstable coronary artery disease: FRISC II prospective randomized multicenter study. Lancet 1999, 354:708–715. CrossRef
- Expert Panel on the Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol on adults (adult treatment panel III). JAMA 2001, 285:2486–2497. This is the most recent of the National Cholesterol Education Program ATP Guidelines, with special sections on patients with ACS, diabetes mellitus, and the metabolic syndrome. CrossRef
- Fresco C, Maggioni AP, Signorini S, et al., on behalf of the LATIN investigators: Variations in lipoprotein levels after myocardial infarction and unstable angina: the LATIN trial. Ital Heart J 2002, 3:587–592.
- Rauoof MA, Iqbal K, Mir MM, Tramboo NA: Measurement of plasma lipids in patients admitted with acute myocardial infarction or unstable angina pectoris. Am J Cardiol 2001, 88:165–167. CrossRef
- Henkin Y, Crystal E, Goldberg Y, et al.: Usefulness of lipoprotein changes during acute coronary syndromes for predicting postdischarge lipoprotein levels. Am J Cardiol 2002, 89:7–11. CrossRef
- The Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357. CrossRef
- Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389. CrossRef
- Sacks FM, Pfeffer MA, Moyé LA, et al., for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009. CrossRef
- Heart Protection Study Collaborative Group: The MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo controlled trial. Lancet 2002, 360:7–22. CrossRef
- Stenestrand U, Wallentin L, for the Swedish Register of Cardiac Intensive Care (RIKS-HIA): Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001, 285:430–436. CrossRef
- Aronow HD, Topol EJ, Roe MT, et al.: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001, 357:1063–1068. CrossRef
- Newby LK, Kristinsson A, Bhapkar MV, et al., for the SYMPHONY and 2nd SYMPHONY Investigators: Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002, 287:3087–3095. CrossRef
- Heeschen C, Hamm CW, Laufs U, et al., on behalf of the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446–1452. CrossRef
- Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins in patients with acute coronary syndromes. Circulation 2003, 107:e27. CrossRef
- Jeffrey S: PACT: early start of statin treatment after ACS safe, but has limited impact at 30 days. www.theheart.org. Accessed January 3, 2004.
- Schwartz GG, Olsson AG, Ezekowitz MD, et al., for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study, a randomized controlled trial. JAMA 2001, 285:1711–1718. The MIRACL study is the first large completed statin trial with hard endpoints conducted in unstable angina and non-ST-segment elevation MI patients. CrossRef
- Cannon CP, Braunwald E, McCabe CH, et al.: Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495–1504. A landmark trial, the PROVE-IT study demonstrated the superiority of intensive lipid lowering with atorvastatin compared to a standard lipid-lowering regimen with pravastatin in ACS patients. This was the first statin trial with hard clinical endpoints to compare two statins, and calls for additional studies comparing statins for the prevention of CHD events. CrossRef
- Blazing MA, de Lemos JA, Dyke CK, et al.: The A-to-Z trial: methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001, 142:211–217. CrossRef
- Brown WV: Benefits of statin therapy in patients with special risks: coronary bypass surgery, stable coronary disease, and acute coronary syndromes. Clin Cardiol 2003, 26(Suppl III):III–13-III-18.
- Ryan TJ, Antman EM, Brooks NH, et al.: 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of acute myocardial infarction). www.acc.org.
- Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee on management of unstable angina). www.acc.org.
- Liuzzo G, Biasucci LM, Gallimore JR, et al.: The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med 1994, 331:417–424. CrossRef
- Park YW, Zhu S, Palaniappan L, et al.: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Int Med 2003, 163:427–436. CrossRef
- Rubins HR, Robins SJ, Collins D, et al., for the Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410–418. CrossRef
- Alberti KG, Zimmet P, for the WHO consultation: Definition, diagnosis, and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Med 1998, 15:539–553. CrossRef
- Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997, 20:1183–1197.
- Moreno R, de Sá EL, López-Sendón J, et al.: Prognosis of medically stabilized unstable angina pectoris with a negative exercise test. Am J Cardiol 1998, 82:662–665. CrossRef
- Malmberg K, Yusuf S, Gerstein HC, et al.: Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. Circulation 2000, 102:1014–1019.
- Granger CB, Califf RM, Young S, et al.: Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group. J Amer Coll Cardiol 1993, 21:920–925. CrossRef
- Norhammer A, Tenerz A, Nilsson G, et al.: Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: a prospective study. Lancet 2002, 359:2140–2144. This study established the superiority (increased sensitivity) of OGTT compared with fasting glucose in screening for diabetes and IGT in patients following acute coronary syndromes. It supports the routine performance of OGTT given the high prevalence of diabetes and IGT in this population. CrossRef
- Tenerz A, Lönnberg I, Berne C, et al.: Myocardial infarction and prevalence of diabetes mellitus: is increased casual blood glucose at admission a reliable criterion for the diagnosis of diabetes? Eur Heart J 2001, 22:1102–1110. CrossRef
- Wahab NN, Cowden EA, Pearce NJ, et al.: Is blood glucose an independent predictor of mortality in acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002, 40:1748–1754. This is one of the larger registries that showed an association between admission hyperglycemia and adverse events in patients with ACS. It demonstrates that nondiabetic patients with hyperglycemia are at as high of a risk as diabetic patients for adverse outcomes. CrossRef
- Foo K, Cooper J, Deaner A, et al.: A single serum glucose measurement predicts adverse outcomes across the whole range of acute coronary syndromes. Heart 2003, 89:512–516. CrossRef
- Sala J, Masiá R, de Molina FJ, et al., for the REGICOR Investigators: Short-term mortality of myocardial infarction patients with diabetes or hyperglycemia during admission. J Epidemiol Commun Health 2002, 56:707–712. CrossRef
- Sodi-Pallares D, Disten A, Ponce de Leon J, et al.: Polarizing solution in myocardial infarction. Amer J Cardiol 1968, 21:275–276. CrossRef
- Fath-Ordoubadi F, Beatt KJ: Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997, 96:1152–1156.
- Malmberg K, Rydén L, Efendic S, et al., on behalf of the DIGAMI study group: Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at one year. J Am Coll Cardiol 1995, 26:57–65. This study is the first large GIK trial to demonstrate a long-term benefit for GIK therapy in diabetic patients admitted for acute MI. CrossRef
- Díaz R, Paolasso EA, Piegas LS, et al., on behalf of the ECLA (Estudios Cardiológicas Latinoamérica) collaborative group: Metabolic modulation of acute myocardial infarction: the ECLA Glucose-Insulin-Potassium Pilot Trial. Circulation 1998, 98:2227–2234. This GIK trial, although overall neutral, suggested that high-dose GIK may improve outcomes in a subset of patients who undergo reperfusion therapy for acute MI.
- Ceremu_y_ski L, Budaj A, Czepiel A, et al., for the Pol-GIK Trial Investigators: Low-dose glucose-insulin-potassium is ineffective in acute myocardial infarction: results of a randomized multicenter Pol-GIK trial. Cardiovasc Drugs Ther 1999, 13:191–200. CrossRef
- van der Horst, IC, Zijlstra F, van’t Hof AW, et al., on behalf of the Zwolle Infarct Study Group: Glucose-insulin-potassium infusion in patients treated with primary angioplasty for acute myocardial infarction. The Glucose-insulin-potassium study: a randomized trial. J Am Coll Cardiol 2003, 42:784–791. This is the most recent GIK trial in acute MI patients undergoing primary PCI. Although overall neutral, there was a suggestion of benefit in patients without signs and symptoms of heart failure. This is awaiting confirmation in another trial planned by these investigators. CrossRef
- Rydén L: Intense metabolic control of diabetic patients with acute myocardial infarction - DIGAMI 2. Karolinska Institute. http://sandshark.kib.ki.se. The website has since been discontinued, but the trial is still ongoing.
- Apstein CS, Taegtmeyer H: Glucose-insulin-potassium in acute myocardial infarction: the time has come for a large, prospective trial. Circulation 1997, 96:1074–1077. This is an outstanding review on the basic science mechanisms behind the benefits of insulin therapy on the ischemic myocardium.
- Rogers WJ, Stanley AW Jr, Breinig JB, et al.: Reduction of hospital mortality rate of acute myocardial infarction with glucose-insulin- potassium infusion. Am Heart J 1976, 92:441–454. CrossRef
- van den Berghe G, Wouters P, Weekers F, et al.: Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345:1359–1367. This trial, though not of acute MI, is of great interest to investigators interested in improving glucose metabolism in acute MI. Intensive insulin therapy with the goal of achieving normoglycemia reduced mortality among surgical ICU patients (the majority cardiac) by 42% compared with conventional therapy for hyperglycemia. On the basis of this trial, a strategy of intensive insulin to achieve normoglycemia should be compared with high-dose GIK and with conventional MI care in acute MI patients. CrossRef
- Nesto RW, Bell D, Bonow RO, et al.: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 2003, 108:2941–2948. CrossRef
- The evaluation and management of dyslipidemia and impaired glucose metabolism during acute coronary syndromes
Current Cardiology Reports
Volume 6, Issue 4 , pp 300-307
- Cover Date
- Print ISSN
- Online ISSN
- Current Medicine Group
- Additional Links